Aviragen Therapeutics
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 1984-01-01
- Employees
- 51
- Market Cap
- -
A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: vapendavir 132 mg capsuleDrug: vapendavir 264 mg tabletDrug: vapendavir 24 mg/mL oral suspension
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2018-11-26
- Lead Sponsor
- Aviragen Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT02877264
- Locations
- 🇺🇸
Aviragen Investigational Site, Saint Paul, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath